---
title: "Can-Fite BioPharma Soars 56% After Cancer Drug Trial Meets Safety Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291457225.md"
description: "Can-Fite BioPharma jumped 56% on positive Phase 2a results for Namodenoson in pancreatic cancer patients."
datetime: "2026-07-01T20:12:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291457225.md)
  - [en](https://longbridge.com/en/news/291457225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291457225.md)
generator: "portal-rs"
---

# Can-Fite BioPharma Soars 56% After Cancer Drug Trial Meets Safety Endpoint

Can-Fite BioPharma(CANF.US) 盘后时段现报**4.63**美元，常规时段涨**55.89%**。

盘中 5 分钟内急涨超 3% 触发异动信号。公司宣布其晚期胰腺导管腺癌患者的 Namodenoson 二期 a 阶段研究达到主要安全终点，并在重度预处理患者中显示出持久的总生存期结果。这些结果支持将该药物推进到与化疗联合的二期 b 阶段试验。

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital](https://longbridge.com/en/news/294682694.md)
- [Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting](https://longbridge.com/en/news/278625962.md)
- [Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients](https://longbridge.com/en/news/291432421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**